Veracyte (NASDAQ:VCYT – Get Free Report) had its price objective lowered by equities research analysts at Morgan Stanley from $23.00 to $22.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “underweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target points to a potential downside of 0.90% […]
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the […]
Veracyte (NASDAQ:VCYT) Research Coverage Started at StockNews com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Perkins Capital Management Inc. reduced its position in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 0.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 121,330 shares of the biotechnology company’s stock after selling 550 shares during the period. Veracyte […]
Company also introduces research-use-only Afirma Genomic Resource for Intelligent Discovery platform for additional insights into thyroid nodules and cancer
.